1,149 results match your criteria Esthesioneuroblastoma


SALL-4 and Beta-Catenin Expression in Sinonasal Teratocarcinosarcoma.

Head Neck Pathol 2021 Jun 9. Epub 2021 Jun 9.

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, MCN CC3322, Nashville, TN, 37232-2561, USA.

Sinonasal teratocarcinosarcoma (SNTCS) is a rare, aggressive malignancy that displays a heterogeneous combination of malignant blastema-like, epithelial and mesenchymal components. Its exact histogenesis is unknown with hypotheses ranging from true germ cell derivation to origin from pluripotent stem cells. However, despite this tumor's multiphenotypic histology, which includes frequent glandular, squamous, and neuroectodermal differentiation similar to adnexal germ cell tumors, SNTCS appears to have some differences from adnexal teratomas. Read More

View Article and Full-Text PDF

Doing Great With DOTATATE: Update on GA-68 DOTATATE Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Evaluation of Sinonasal Tumors.

Top Magn Reson Imaging 2021 Jun;30(3):151-158

Department of Radiology, Northwell Health Lenox Hill Hospital, New York, NY.

Abstract: Sinonasal tumors are relatively rare and radiographically challenging to evaluate due to their wide variety of pathologies and imaging features. However, sinonasal tumors possessing somatostatin receptor overexpression have the benefit of utilizing a multimodality anatomic and functional imaging for a more comprehensive evaluation. This is particularly evident with esthesioneuroblastoma, with computed tomography and magnetic resonance imaging defining the anatomic extent of the tumor, whereas somatostatin receptor imaging, particularly with gallium-68 DOTATATE positron emission tomography/computed tomography, is used to assess the presence of metastatic disease for staging purposes as well as in the surveillance for tumor recurrence. Read More

View Article and Full-Text PDF

Skull Base Primary Ewing Sarcoma: A Radiological Experience of a Rare Disease in an Atypical Location.

Am J Case Rep 2021 Jun 5;22:e930384. Epub 2021 Jun 5.

Department of Radiology, School of Medical Sciences, University of Science Malaysia, Kota Bharu, Malaysia.

BACKGROUND Ewing sarcoma and primitive neuroectodermal tumor are rare tumors grouped under the spectrum of the Ewing sarcoma family of tumors. These highly malignant tumors involve the bones and commonly occur in children. Ewing sarcoma of the skull bone accounts for only 1% of all Ewing sarcomas, with primary skull base Ewing sarcoma occurring in less than 1% of cases. Read More

View Article and Full-Text PDF

A population-based analysis of clinical features and lymph node dissection in head and neck malignant neurogenic tumors.

BMC Cancer 2021 May 24;21(1):598. Epub 2021 May 24.

Department of Otolaryngology, Head and Neck Surgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.

Background: The influence of lymph node dissection (LND) on survival in patients with head and neck neurogenic tumors remains unclear. We aimed to determine the effect of LND on the outcomes of patients with head and neck neurogenic tumors.

Methods: Data of patients with surgically treated head and neck neurogenic tumors were identified from the Surveillance, Epidemiology, and End Results (SEER) database (1975-2016) to investigate the relationship between LND and clinical outcomes by survival analysis. Read More

View Article and Full-Text PDF

The role of chemotherapy in the management of olfactory neuroblastoma: A 40-year surveillance, epidemiology, and end results registry study.

Health Sci Rep 2021 Jun 2;4(2):e257. Epub 2021 May 2.

Department of Radiation Oncology Beaumont Health Royal Oak Michigan.

Background: In this retrospective surveillance, epidemiology, and end results (SEER) registry analysis, we investigated the role of chemotherapy (CT) in the treatment of olfactory neuroblastoma (ON), an exceedingly rare sino-nasal tumor typically treated with surgery and/or radiation therapy (RT).

Methods: We analyzed all patients in the SEER registry diagnosed with a single primary malignancy of ON, a primary tumor site within the nasal cavity or surrounding sinuses, sufficient staging information to derive Kadish staging, and >0 days of survival, ensuring follow-up data. Receipt of CT in the SEER registry was documented as either Yes or No/Unknown. Read More

View Article and Full-Text PDF

SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications.

Head Neck Pathol 2021 Apr 30. Epub 2021 Apr 30.

Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Somatostatin receptor 2 (SSTR2) expression has previously been documented in olfactory neuroblastoma (ONB). Here, we fully characterize SSTR2 expression in ONB and correlate staining results with clinicopathologic parameters including Hyams grade. We also assess SSTR2 immunohistochemistry expression in various histologic mimics of ONB to assess its diagnostic functionality. Read More

View Article and Full-Text PDF

Characteristics and overall survival in pediatric versus adult esthesioneuroblastoma: A population-based study.

Int J Pediatr Otorhinolaryngol 2021 May 28;144:110696. Epub 2021 Mar 28.

Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, CA, USA; Department of Neurological Surgery, University of California, Irvine, CA, USA. Electronic address:

Background: Esthesioneuroblastoma (ENB) is an uncommon sinonasal malignancy and is even less common in the pediatric population.

Objective: The purpose of this study is to compare characteristics and outcomes of ENB between adult and pediatric patients.

Methods: The National Cancer Database was queried for patients with histologically proven ENB of the nasal cavity and paranasal sinuses, and then baseline characteristics, treatment, and survival data compared between the pediatric (age < 18 years) and adult (age ≥ 18 years) populations. Read More

View Article and Full-Text PDF

[Clinical analysis of 31 cases of esthesioneuroblastoma].

Authors:
Xindi He Ying Wang

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2021 Apr;35(4):338-340

Department of Rhinology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou,450052,China.

To investigate the clinical characteristics and prognostic factors of esthesioneuroblastoma. The clinical data of 31 patients with esthesioneuroblastoma were retrospectively studied. The average time from first onset to diagnosis in 31 patients was 7. Read More

View Article and Full-Text PDF

[Diagonistic and prognostic analysis of olfactory neuroblastoma].

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2021 Mar;35(3):224-228

Department of Otolaryngology Head and Neck Surgery,Affiliated Hospital of Qingdao University,Qingdao,266003,China.

To explore the therapeutic effect and prognostic risk factors of olfactory neuroblastoma. Retrospective analysis of clinical data of 31 patients with olfactory neuroblastoma. The Kaplan-Meier method was used for survival analysis to calculate the overall survival rate and progress-free survival rate. Read More

View Article and Full-Text PDF

The value of Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series.

Head Neck 2021 Jun 31;43(6):E30-E40. Epub 2021 Mar 31.

Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Background: Gallium-DOTATATE ( Ga-DOTATATE) is a somatostatin analog used as a PET tracer to successfully identify neuroendocrine tumors (NETs). Due to the rarity of sinonasal NETs, there are few recommendations for Ga-DOTATATE imaging in these patients.

Methods: We discussed the impact of Ga-DOTATATE imaging on the management of six sinonasal NET cases and reviewed existing literature. Read More

View Article and Full-Text PDF

68Ga-DOTATOC PET/CT and MR in the Evaluation of Meningeal Metastasis From Esthesioneuroblastoma: A Case Report.

Clin Nucl Med 2021 Jul;46(7):e378-e380

From the Nuclear Medicine, University of Brescia and ASST Spedali Civili Brescia.

Abstract: Esthesioneuroblastoma is a rare malignant tumor arising from olfactory neuroepithelium. PET/CT with different tracers such as 18F-FDG and 68Ga-somatostatin-receptor tracers has demonstrated its utility for the evaluation of disease. We present the case of a woman previously treated for esthesioneuroblastoma performing MR and 18Ga-DOTATOC PET/CT demonstrating dural metastasis of disease with a strong correspondence between conventional and functional imaging. Read More

View Article and Full-Text PDF

Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis.

J Neurooncol 2021 May 26;153(1):15-22. Epub 2021 Mar 26.

Department of Neurosurgery, Oklahoma University Health Sciences Center, Oklahoma City, OK, 73104, USA.

Introduction: Esthesioneuroblastoma (ENB) is an uncommon primary sinonasal tumor which can extend intracranially. Exactly how to classify them pathologically still remains discrepant; the Hyams grading system, for example, has not been universally adopted. This individual patient data (IPD) meta-analysis aimed to investigate the prognostic implication of each Hyams grade on patient outcomes. Read More

View Article and Full-Text PDF

Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma.

Front Oncol 2021 4;11:624960. Epub 2021 Mar 4.

Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.

Esthesioneuroblastoma (ENB) is a rare sinonasal malignancy, lacking a unified staging system and treatment. Management at a single center was retrospectively evaluated to inform future treatment options and prognostic factors. Clinical data of 64 consecutive ENB patients, including prognostic factors and treatment methods, were reviewed retrospectively. Read More

View Article and Full-Text PDF

Radiation-induced intracranial osteosarcoma of the anterior skull base after treatment of esthesioneuroblastoma.

BMJ Case Rep 2021 Jan 18;14(1). Epub 2021 Jan 18.

Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.

Esthesioneuroblastoma (ENB) is an uncommon sinonasal cancer of the olfactory neuroepithelium that is typically treated with surgical resection followed by radiation therapy. Radiation-induced intracranial osteosarcoma of the skull base is a rare but devastating long-term complication of radiation therapy in this region. Here, we present a case of an 82-year-old patient who developed radiation-induced osteosarcoma of the anterior skull base and paranasal sinuses 10 years after radiation therapy following resection of an ENB. Read More

View Article and Full-Text PDF
January 2021

Geographic and Socioeconomic Factors on Survival in Esthesioneuroblastoma.

Laryngoscope 2021 07 21;131(7):E2162-E2168. Epub 2020 Dec 21.

Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.

Objectives: Esthesioneuroblastoma (ENB) is a rare sinonasal malignancy with little known regarding how regional and socioeconomic differences in the United States alter disease survival. The aim of this study is to explore the geographic difference in clinical features, socioeconomic factors, and survival outcomes of ENB patients.

Methods: ENB cases were extracted from the Surveillance, Epidemiology, and End Results registry from 1975-2016. Read More

View Article and Full-Text PDF

Orbital invasion by Esthesioneuroblastoma: a comparative case series and review of literature.

Orbit 2020 Dec 14:1-14. Epub 2020 Dec 14.

Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

To review the current literature on esthesioneuroblastoma (ENB) as it pertains to clinical features, grading systems, treatment options, and survival.: A literature search in PubMed was performed to include all articles published in English with orbit involving ENB. Only articles that included each patient's demographics, tumor stage, treatment, or survival were included. Read More

View Article and Full-Text PDF
December 2020

Proposal of a TNM classification-based staging system for esthesioneuroblastoma: More precise prediction of prognosis.

Head Neck 2021 Apr 10;43(4):1097-1104. Epub 2020 Dec 10.

Department of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: Esthesioneuroblastoma (ENB) is a rare malignant neoplasm. Currently, no consistent and universal staging system for ENB exists. The aim of this study is to propose a TNM-based classification. Read More

View Article and Full-Text PDF

C19MC amplification and expression of Lin28A and Olig2 in the classification of embryonal tumors of the central nervous system: A 14-year retrospective study from a tertiary care center.

Childs Nerv Syst 2021 Apr 24;37(4):1067-1075. Epub 2020 Nov 24.

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India, 110029.

Introduction: CNS embryonal tumors (CET) other than medulloblastomas (MB) and atypical teratoid/rhabdoid tumors (AT/RTs), previously designated as 'central nervous system primitive neuroectodermal tumors' ('CNS PNETs'), are a heterogenous subset of tumors with poorly defined diagnostic criteria. Other than the subset of embryonal tumor with multilayered rosettes (ETMR) defined by C19MC amplification, most CETs are diagnosed by exclusion of other molecularly defined entities and histological mimics including MB, AT/RTs, and high-grade gliomas, and termed as CET, not otherwise specified (NOS) in the 2016 WHO classification.

Aim: To reclassify 'CNS PNETs' as per WHO 2016, and estimate the true proportion of CET, NOS in a tertiary healthcare setting, and to evaluate the diagnostic utility of C19MC amplification, Lin28A and Olig2 expression in the subclassification of CETs. Read More

View Article and Full-Text PDF

Occult olfactory neuroblastoma presenting with multiple bone metastases: a case report.

Medicine (Baltimore) 2020 Nov;99(48):e22630

Department of Hematology, The First Hospital of Lanzhou University.

Rationable: Olfactory neuroblastoma (ONB) is a rare malignant tumor of the nasal cavity, the primary local symptoms are usually inconspicuous. Patients are often admitted to various specialties based on different primary symptoms, which may result in delayed diagnosis and even a misdiagnosis.

Patient Concerns: Here we report a case of ONB that presented initially as multiple ostealgia without any local symptoms of the tumor and primarily misdiagnosed as multiple myeloma. Read More

View Article and Full-Text PDF
November 2020

Surgery as Single-Modality Treatment for Early-Stage Olfactory Neuroblastoma: An Institutional Experience, Systematic Review and Meta-analysis.

Am J Rhinol Allergy 2020 Nov 11:1945892420973163. Epub 2020 Nov 11.

Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Zurich, Zurich, Switzerland.

Background: For olfactory neuroblastoma (ONB), the combination of surgical tumor resection and radiation therapy (RT) has been considered the "gold standard" in treatment protocols intended to cure.

Objective: To summarize evidence on the treatment of ONB using surgery alone.

Methods: A retrospective institutional case series, a systematic review of the literature, and an individual patient data (IPD) meta-analysis on only surgically treated ONB patients. Read More

View Article and Full-Text PDF
November 2020

Limited utility of 5-ALA optical fluorescence in endoscopic endonasal skull base surgery: a multicenter retrospective study.

J Neurosurg 2020 Oct 30:1-7. Epub 2020 Oct 30.

3Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, New York.

Objective: Incomplete resection of skull base pathology may result in local tumor recurrence. This study investigates the utility of 5-aminolevulinic acid (5-ALA) fluorescence during endoscopic endonasal approaches (EEAs) to increase visibility of pathologic tissue.

Methods: This retrospective multicenter series comprises patients with planned resection of an anterior skull base lesion who received preoperative 5-ALA at two tertiary care centers. Read More

View Article and Full-Text PDF
October 2020

Short-Term Morbidity and Predictors of Adverse Events Following Esthesioneuroblastoma Surgery.

Am J Rhinol Allergy 2020 Oct 29:1945892420970468. Epub 2020 Oct 29.

Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California.

Introduction: The short-term adverse events and predictors of morbidity in surgical resection of esthesioneuroblastoma (ENB) are largely unknown, and investigating these variables can help direct planning for at-risk patients.

Methods: The 2005-2017 National Surgical Quality Improvement Program database was queried to identify patients with a diagnosis of ENB undergoing skull base surgery for tumor resection. Information regarding demographics, patient morbidity score, pre-operative and intra-operative data, and post-operative outcomes were extracted. Read More

View Article and Full-Text PDF
October 2020

A novel nomogram to predict the overall survival in esthesinoeroblastoma.

BMC Cancer 2020 Oct 14;20(1):993. Epub 2020 Oct 14.

The Otorhinolaryngology Hospital, First Affiliated Hospital of Sun Yat-sen University, No.58 Zhongshan Er Road, Guangzhou, Guangzhou, 510080, P.R. China.

Background: Increasing evidence indicates that the pathology and the modified Kadish system have some influence on the prognosis of esthesioneuroblastoma (ENB). However, an accurate system to combine pathology with a modified Kadish system has not been established.

Methods: This study aimed to set up and evaluate a model to predict overall survival (OS) accurately in ENB, including clinical characteristics, treatment and pathological variables. Read More

View Article and Full-Text PDF
October 2020

Facial disfigurement due to olfactory neuroblastoma: beauty regained with chemotherapy.

Cancer Rep (Hoboken) 2021 02 8;4(1):e1303. Epub 2020 Oct 8.

Department of Medical Oncology, Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

Background: Olfactory neuroblastoma (ONB) is a sinonasal malignancy seldom seen in clinical practice. It is also known by various other names like esthesioneuroblastoma, esthesioneuroepithelioma, esthesioneurocytoma, and esthesioneuroma. Surgery and radiation therapy are considered as standard treatment modalities for ONB; however, the role of chemotherapy is not well established. Read More

View Article and Full-Text PDF
February 2021

Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience.

Cancer Manag Res 2020 10;12:8355-8362. Epub 2020 Sep 10.

Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, People's Republic of China.

Purpose: Esthesioneuroblastoma (ENB) is a type of rare malignant neoplasm of the sinonasal cavity. Optimal treatment for ENB is still controversial. A retrospective study was conducted to identify the clinical outcome and optimal treatment for ENB in the era of intensity-modulated radiation therapy (IMRT). Read More

View Article and Full-Text PDF
September 2020

Intensity-modulated particle beam radiation therapy in the management of olfactory neuroblastoma.

Ann Transl Med 2020 Aug;8(15):926

Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.

Background: To report the clinical experience and short-term efficacy in the management of olfactory neuroblastoma (ONB).

Methods: We performed a retrospective analysis of 12 ONB patients treated with particle beam radiation therapy (PBRT) between 12/2015 and 5/2019 at the Shanghai Proton and Heavy Ion Center. Four (33. Read More

View Article and Full-Text PDF